Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $6,836,989.98 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 11,366 shares of the firm’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $601.53, for a total transaction of $6,836,989.98. Following the completion of the transaction, the chief executive officer directly owned 604,436 shares of the company’s stock, valued at $363,586,387.08. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Medpace Stock Performance

MEDP traded down $3.45 during trading on Friday, reaching $578.50. 215,633 shares of the stock were exchanged, compared to its average volume of 352,984. The stock has a market cap of $16.15 billion, a P/E ratio of 33.91, a price-to-earnings-growth ratio of 2.66 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The stock’s 50 day moving average price is $533.75 and its two-hundred day moving average price is $491.74.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter last year, the company posted $3.10 earnings per share. The company’s revenue for the quarter was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Equities research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MEDP. BMO Capital Markets raised their target price on shares of Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. TD Cowen upped their price objective on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Royal Bank Of Canada boosted their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, Medpace has an average rating of “Hold” and an average target price of $584.18.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. NewEdge Advisors LLC lifted its position in Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after acquiring an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Medpace by 3.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after purchasing an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. grew its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Sivia Capital Partners LLC bought a new position in shares of Medpace during the second quarter worth approximately $296,000. Finally, M&T Bank Corp increased its stake in shares of Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after purchasing an additional 31 shares during the period. 77.98% of the stock is owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.